

# Cristian Tomasetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8749690/publications.pdf>

Version: 2024-02-01

47  
papers

9,914  
citations

159358

30  
h-index

214527

47  
g-index

52  
all docs

52  
docs citations

52  
times ranked

14359  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the impact of multicancer early detection testing on health and economic outcomes: Toward a decision modeling strategy. <i>Cancer</i> , 2022, 128, 892-908.	2.0	7
2	Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2261-2272.	13.9	337
3	Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA100-LBA100.	0.8	5
4	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021, 148, 1014-1026.	2.3	77
5	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. <i>ELife</i> , 2021, 10, .	2.8	12
6	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003620.	3.9	88
7	Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands. <i>Nature Biotechnology</i> , 2021, 39, 1220-1227.	9.4	40
8	Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 733-742.	3.7	31
9	Revisiting the tumorigenesis timeline with a data-driven generative model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 857-864.	3.3	44
10	Assessing aneuploidy with repetitive element sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4858-4863.	3.3	50
11	Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. <i>Science</i> , 2020, 369, .	6.0	351
12	A multimodality test to guide the management of patients with a pancreatic cyst. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	129
13	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. <i>JAMA Oncology</i> , 2019, 5, 1710.	3.4	383
14	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. <i>International Journal of Cancer</i> , 2019, 145, 540-547.	2.3	15
15	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20482-20488.	3.3	63
16	Mutated clones are the new normal. <i>Science</i> , 2019, 364, 938-939.	6.0	28
17	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1118.	3.4	152
18	Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. <i>Modern Pathology</i> , 2019, 32, 1544-1550.	2.9	45

#	ARTICLE	IF	CITATIONS
19	1124 A MULTI-MODALITY TEST TO GUIDE THE MANAGEMENT OF PATIENTS WITH PANCREATIC CYSTS. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB143-AB144.	0.5	1
20	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. <i>Journal of Pathology</i> , 2019, 248, 41-50.	2.1	84
21	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , 2019, 68, 663-671.	6.1	234
22	Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.	6.0	1,872
23	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
24	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. <i>ELife</i> , 2018, 7, .	2.8	118
25	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3516-3516.	0.8	19
26	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16206-e16206.	0.8	4
27	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1835-1848.	13.9	451
28	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. <i>Science</i> , 2017, 355, 1330-1334.	6.0	803
29	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10202-10207.	3.3	438
30	Role of stem-cell divisions in cancer risk. <i>Nature</i> , 2017, 548, E13-E14.	13.7	42
31	On the slope of the regression between stem cell divisions and cancer risk, and the lack of correlation between stem cell divisions and environmental factors-associated cancer risk. <i>PLoS ONE</i> , 2017, 12, e0175535.	1.1	12
32	Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9846-9851.	3.3	178
33	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. <i>Science Translational Medicine</i> , 2016, 8, 346ra92.	5.8	1,036
34	Variation in cancer risk among tissues can be explained by the number of stem cell divisions. <i>Science</i> , 2015, 347, 78-81.	6.0	1,561
35	Cancer risk: Role of environmentâ€™Response. <i>Science</i> , 2015, 347, 729-731.	6.0	59
36	The (not so) immortal strand hypothesis. <i>Stem Cell Research</i> , 2015, 14, 238-241.	0.3	22

#	ARTICLE	IF	CITATIONS
37	Only three driver gene mutations are required for the development of lung and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 118-123.	3.3	325
38	An argument for mechanism-based statistical inference in cancer. Human Genetics, 2015, 134, 479-495.	1.8	9
39	Drug Resistance. Advances in Experimental Medicine and Biology, 2014, 844, 303-316.	0.8	6
40	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1999-2004.	3.3	348
41	Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Research, 2013, 2, 152.	0.8	2
42	Stochastic Modelling of Multiple Random Genetic Mutations Under the Cancer Stem Cell Hypothesis. Mathematical Population Studies, 2012, 19, 200-213.	0.8	0
43	On the Probability of Random Genetic Mutations for Various Types of Tumor Growth. Bulletin of Mathematical Biology, 2012, 74, 1379-1395.	0.9	11
44	The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia. Blood, 2012, 120, 4436-4436.	0.6	0
45	A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells. Blood Cancer Journal, 2011, 1, e19-e19.	2.8	7
46	Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16766-16771.	3.3	90
47	An elementary approach to modeling drug resistance in cancer. Mathematical Biosciences and Engineering, 2010, 7, 905-918.	1.0	52